Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Oloctinebart Biologics Sequence Review Report 2026: LGALS3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Oloctinebart Biologics Sequence Review Report 2026: LGALS3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oloctinebart, an antibody targeting LGALS3.
Read →
Lunaxafusp Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Lunaxafusp Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lunaxafusp, an antibody targeting HER2.
Read →
Eglatoprutug Biologics Sequence Review Report 2026: KIT Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Eglatoprutug Biologics Sequence Review Report 2026: KIT Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eglatoprutug, an antibody targeting KIT.
Read →
Zeleciment Biologics Sequence Review Report 2026: TFRC Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Zeleciment Biologics Sequence Review Report 2026: TFRC Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeleciment, an antibody targeting TFRC.
Read →
Vixticibart Biologics Sequence Review Report 2026: NPR1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Vixticibart Biologics Sequence Review Report 2026: NPR1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vixticibart, an antibody targeting NPR1.
Read →
Usilnetug Biologics Sequence Review Report 2026: APP Aβ N3pGlu Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Usilnetug Biologics Sequence Review Report 2026: APP Aβ N3pGlu Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Usilnetug, an antibody targeting APP Aβ N3pGlu.
Read →
Trosunilimab Biologics Sequence Review Report 2026: ITGA4B7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Trosunilimab Biologics Sequence Review Report 2026: ITGA4B7 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trosunilimab, an antibody targeting ITGA4B7.
Read →
Timcevibart Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Timcevibart Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Timcevibart, an antibody targeting SARS-CoV-2 Spike RBD.
Read →
Pegrizeprument Biologics Sequence Review Report 2026: CD28 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Pegrizeprument Biologics Sequence Review Report 2026: CD28 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pegrizeprument, an antibody targeting CD28.
Read →
Olintatug Biologics Sequence Review Report 2026: KAAG1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Olintatug Biologics Sequence Review Report 2026: KAAG1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Olintatug, an antibody targeting KAAG1.
Read →
Avitotamig Biologics Sequence Review Report 2026: SIGLEC3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Avitotamig Biologics Sequence Review Report 2026: SIGLEC3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avitotamig, an antibody targeting SIGLEC3.
Read →
Rilogrotug Biologics Sequence Review Report 2026: GDF15 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Rilogrotug Biologics Sequence Review Report 2026: GDF15 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rilogrotug, an antibody targeting GDF15.
Read →